Conjugate Or Complex Includes Virus Or Componenet Thereof Patents (Class 424/196.11)
  • Patent number: 11110122
    Abstract: The present invention is directed to methods of inducing a phenotypic change in a population of monocytes and/or macrophages. The method includes administering to the population of monocytes and/or macrophages, a macrophage stimulating agent coupled to a carrier molecule, wherein the carrier molecule facilitates macropinocytic uptake of the agent by monocytes and macrophages in the population and is defective in neonatal Fc receptor binding, wherein the administering induces a phenotypic change in the monocytes and macrophages in the population.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: September 7, 2021
    Assignee: NEW YORK UNIVERSITY
    Inventors: Dafna Bar-Sagi, Jane Cullis, Craig Ramirez
  • Patent number: 11097000
    Abstract: The disclosure provides various immunogens comprising a repeat unit of saccharide of Klebsiella pneumoniae CPS, which has a formula selected from the group consisting of Formulae (I) to (VI) as described herein. Also provided are vaccines including one or more immunogens selected from Formula (I) to (VI) and methods of eliciting an immune response against a Klebsiella pneumoniae and preventing infection of Klebsiella pneumoniae by using an immunogen of the invention.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: August 24, 2021
    Assignees: NATIONAL TAIWAN UNIVERSITY, ACADEMIA SINICA
    Inventors: Jin-Town Wang, Shih-Hsiung Wu, Chung-Yi Wu
  • Patent number: 11058760
    Abstract: Provided herein are compositions of virus like particles (VLPs) of poliovirus (PV) that have one or more stabilizing mutations that confer a higher degree of thermostability to the N-antigenic form of the VLPs. These VLPs are non-infectious, and thus safer for use in vaccine development and administration to clinical subjects.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 13, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: James B. Flanegan, Robert McKenna, Christopher Daniel Boone, Sushma Abraham Ogram, Barbara Joan Morasco
  • Patent number: 11053292
    Abstract: In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of GM-CSF and a polypeptide IL-4. Typically, the GM-CSF and IL-4 are connected by a linker, e.g., polypeptide. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such nucleic acids.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: July 6, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Jiusheng Deng
  • Patent number: 10729763
    Abstract: The disclosure describes compositions containing PEGylated compounds using linkers, bivalent polysaccharide covalent PEG compounds, and methods of bivalent polysaccharide-PEG compounds in the development of multivalent vaccines. PEGylated conjugation of capsular polysaccharides to carrier proteins is carried out using homo-bifunctional and/or hetero-bifunctional linkers of specific lengths. Incorporation of bifunctional PEG linkers induces higher titers of functional antibodies with high avidity, eliciting higher immunologic memory, and reduced carrier protein effect. This provides immunochemically cross-reactive capsular polysaccharides wherein one or more cross-reactive capsular polysaccharides are covalently PEG compounded sequentially or concurrently to carrier protein using bifunctional linkers bearing the same or different functional groups.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: August 4, 2020
    Assignee: Inventprise, LLC
    Inventors: Subhash V. Kapre, Anup K. Datta
  • Patent number: 10688170
    Abstract: The disclosure describes compositions containing conjugates using novel linkers, bivalent polysaccharide conjugates, and methods of bivalent polysaccharide conjugation in the development of multivalent conjugate vaccines. Conjugation of capsular polysaccharides to carrier proteins is carried out using homo-bifunctional and/or hetero-bifunctional linkers of specific lengths. Incorporation of the linkers and their use in bifunctional linkers induces higher titers of functional antibodies with high avidity, eliciting higher immunologic memory, and reduced carrier protein effect. This provides immunochemically cross-reactive capsular polysaccharides wherein one or more cross-reactive capsular polysaccharides are conjugated sequentially or concurrently to carrier protein using bifunctional linkers bearing the same or different functional groups.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: June 23, 2020
    Assignee: Inventprise, LLC
    Inventors: Subhash V. Kapre, Anup K. Datta
  • Patent number: 10428116
    Abstract: A peptide comprising the rhinovirus immunogen peptide of the rhinovirus structural protein 1 (VP1) of rhinovirus C and related vaccines and therapeutic compositions is disclosed.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: October 1, 2019
    Assignees: Wisconsin Alumni Research Foundation, Purdue Research Foundation
    Inventors: Ann C. Palmenberg, Marchel Goldsby Hill, Kelly Elizabeth Watters, Michael G. Rossman, Yue Liu
  • Patent number: 10335150
    Abstract: A Staple cartridge assembly for stapling patient tissue is disclosed comprising a staple cartridge including a deck. The deck includes a plurality of staple cavities and is configured to support the tissue. The staple cartridge assembly further includes a plurality of staples removably stored in the staple cavities and an implantable layer positioned adjacent to the deck. The implantable layer comprises a composite absorbable material, wherein the composite absorbable material comprises at least two distinct fibrous materials. At least one freeze-dried medicament is releasably held on at least one of the fibrous materials. The staple cartridge assembly further includes a liquid impermeable film wrapped around the staple cartridge and the implantable layer.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: July 2, 2019
    Assignee: Ethicon LLC
    Inventor: Frederick E. Shelton, IV
  • Patent number: 10293041
    Abstract: Stable immunogenic composition capable of eliciting a robust and durable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising at least one antigen consisting of a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores. Method making and using a stable immunogenic composition capable of eliciting a stable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising providing an immunogenic composition comprising at least one antigen comprising a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores and administering the immunogenic composition to an individual.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: May 21, 2019
    Assignee: Soligenix, Inc.
    Inventors: Robert Brey, Christopher Schaber
  • Patent number: 10208102
    Abstract: The present invention relates to albumin variants with an improved affinity for the neonatal Fc receptor (FcRn) and uses thereof, and in particular to the use of such albumin variants as carriers for immunogens. In some embodiments, the present invention relates to vaccines (e.g., vaccines for mucosal delivery) comprising albumin/immunogen fusion proteins.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: February 19, 2019
    Assignee: UNIVERSITY OF OSLO
    Inventors: Jan Terje Andersen, Inger Sandlie, Malin Bern
  • Patent number: 10105436
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: October 23, 2018
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Aladar Szalay, Boris Minev
  • Patent number: 10076569
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: September 18, 2018
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Aladar Szalay, Boris Minev
  • Patent number: 10076567
    Abstract: The present invention relates to peptides and compositions suitable for use in inducing anti-HIV-1 antibodies. The compositions comprise HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such compositions.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: September 18, 2018
    Assignees: DUKE UNIVERSITY, LOS ALAMOS NATIONAL SECURITY, LLC
    Inventors: Barton F. Haynes, Bette T. Korber, S. Munir Alam
  • Patent number: 9895436
    Abstract: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: February 20, 2018
    Assignee: Genocea Biosciences, Inc.
    Inventors: Deborah Long, Jessica Flechtner, Mojca Skoberne, George R. Siber
  • Patent number: 9789179
    Abstract: The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: October 17, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • Patent number: 9731002
    Abstract: HIV-1 envelope proteins and fragments that possess naturally occurring and novel engineered epitopes that can be used to elicit (and are recognized by) broadly neutralizing antibodies.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: August 15, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Phillip Berman, Gwen Tatsuno, Bin Yu, Javier Morales, Kathryn Mesa
  • Patent number: 9675687
    Abstract: Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 13, 2017
    Assignee: University of Massachusetts
    Inventors: Shan Lu, Shixia Wang
  • Patent number: 9284355
    Abstract: This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of vaccinating a subject against HSV and treating, impeding, inhibiting, reducing the incidence of, or suppressing an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention.
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: March 15, 2016
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Harvey Friedman, Sita Awashi, John Lubinski
  • Patent number: 9205147
    Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: December 8, 2015
    Assignee: Novavax AB
    Inventors: Bror Morein, Karin Lövgren Bengtsson
  • Patent number: 9114098
    Abstract: A method for using inactivated Japanese encephalitis virus particles as an adjuvant of a vaccine is provided. A method for using inactivated Japanese encephalitis virus (JEV) particles as an adjuvant of various vaccines or a mixed vaccine, said JEV particles being obtained by inoculating JEV Beijing-1 strain to Vero cells, culturing said JEV-infected cells to give cultured cells or culture supernatant, purifying JEV particles from said cultured cells or culture supernatant and inactivating said JEV particles with formalin, a method for preparing a (mixed) vaccine which comprises a step of letting inactivated Japanese encephalitis virus be contained, and a mixed vaccine prepared by said method.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: August 25, 2015
    Assignee: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Makoto Moriyama, Kazuyoshi Kaminaka, Junichi Matsuda, Chikateru Nozaki
  • Patent number: 9023364
    Abstract: Disclosed is a vaccine antigen capable of inducing a cross-reacting and neutralizing antibody directed against a high-risk-type human papillomavirus. Specifically disclosed are: a chimeric protein comprising an L2-epitope of a human papillomavirus (HPV) type-16 inserted in a loop region of a human papillomavirus type-16 L1 protein; and a capsid which is a particle formed by the chimeric protein. The loop region to which the L2-epitope is to be inserted is located between an amino acid residue at position-430 and an amino acid residue at position-433. The L2-epitope has an amino acid sequence represented by any one of the following formulae: LYKTCKQAGTCPPDIIPKVEG (SEQ ID NO: 2) (18-38 L2-epitope); GGLGIGTGSGTGGRTGYIPL (SEQ ID NO: 3) (56-75 L2-epitope); and DPVGPLDPSIVSLVEESSFI (SEQ ID NO: 4) (96-115 L2-epitope).
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: May 5, 2015
    Assignee: Japan Health Sciences Foundation
    Inventors: Tadahito Kanda, Kazunari Kondo
  • Patent number: 8999347
    Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. Furthermore, particles with the specific ratio can be prepared by employing yeast, Saccharomyces cerevisiae or Pichia pastoris. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. S antigen derived from Hepatitis B virus, and characterized in that the ratio of S to CSV-S is in the range 0.1 to 1. Suitably, the ratio of S to CSV-S is in the range 0.19 to 0.30 or 0.68 to 0.80.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: April 7, 2015
    Assignee: GlaxoSmithKline Biologicals, SA
    Inventors: Joseph D Cohen, Martine Marchand
  • Publication number: 20150093410
    Abstract: The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.
    Type: Application
    Filed: November 3, 2014
    Publication date: April 2, 2015
    Inventors: Weihsu CHEN, Weili YAN, Kenya JOHNSON, Gregory CONN, Frank BEDU-ADDO, Leaf HUANG
  • Publication number: 20150056244
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 26, 2015
    Applicant: SENTINEXT THERAPEUTICS SDN BHD
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Publication number: 20150050317
    Abstract: A means to elicit a cytotoxic immune response as a result of injecting antigen encoding expression constructs. Minimalistic expression constructs are used that comprise a promoter, a coding sequence and a terminator, and hairpin-shaped oligonucleotides on their ends, to the loop of which cationic peptides are covalently attached. These peptide-coupled expression constructs lead to a cell mediated response type after intradermal injection. The use of a DNA expression construct operable in eucaryotic cells for making a vaccine for intradermal injection to elicit a type 1 cell mediated immune mediated immune response is described.
    Type: Application
    Filed: August 19, 2013
    Publication date: February 19, 2015
    Applicant: MOLOGEN AG
    Inventors: Sonia Moreno-Lopez, Marcos Timon-Jimenez
  • Patent number: 8956627
    Abstract: The present invention relates to a method of inducing the production in a patient of anti-HIV antibodies. The method comprises administering to a patient in need thereof an amount of at least one liposome-peptide conjugate in an amount sufficient to effect that induction. The peptide comprises a membrane external proximal region (MPER) epitope and the liposome comprises lysophosphorylcholine or phosphatidylserine.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: February 17, 2015
    Assignee: Duke University
    Inventors: Barton F. Haynes, S. Munir Alam, Hua-Xin Liao
  • Patent number: 8956625
    Abstract: The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus are provided.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: February 17, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Herve De Hemptinne, Michel Duchene, Anne Mary, Marc Sonveaux
  • Patent number: 8951532
    Abstract: The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life cycle. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in a diagnostic procedure designed to detect these bacteria.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: February 10, 2015
    Assignee: Alere Scarborough, Inc.
    Inventors: Brion Mermer, William J. Palin, Nancy Turcotte
  • Publication number: 20150037367
    Abstract: Contemplated compositions, devices, and methods are drawn to various antigens from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.
    Type: Application
    Filed: June 29, 2012
    Publication date: February 5, 2015
    Inventors: David Huw Davies, Xiaowu Liang, Philip Felgner
  • Patent number: 8940307
    Abstract: The present invention also relates to a method of reducing metastases in a subject comprising administering to the subject a composition comprising a multifunctional molecule comprising a first part which is capable of binding to an antigen bearing target and a second part which is capable of binding to a cell.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: January 27, 2015
    Assignee: Opsanitx LLC
    Inventors: Andrew H. Segal, Elihu Young
  • Publication number: 20150024002
    Abstract: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.
    Type: Application
    Filed: August 20, 2014
    Publication date: January 22, 2015
    Inventors: Silvia Perri, John Polo, Yasushi Uematsu, Catherine Greer
  • Patent number: 8920812
    Abstract: The present invention relates to chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus GAG-based virus-like particles (VLPs). The present invention also includes methods of making and using such chimeric VLPs. In certain embodiments, the GAG polypeptide of the chimeric VLPs comprises an HIV or ALV GAG polypeptide.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: December 30, 2014
    Assignee: Takeda Vaccines, Inc.
    Inventor: Joel R. Haynes
  • Publication number: 20140370049
    Abstract: The subject matter of the invention is a method for preparing a vaccine composition comprising at least aluminium oxyhydroxide (AlOOH), and at least the hepatitis B surface antigen and the Haemophilus influenzae type b antigen. According to the invention, the hepatitis B surface antigen is kept adsorbed on the AlOOH, whereas the Hib antigen is kept nonadsorbed. To this end: the hepatitis B surface antigen is adsorbed onto AlOOH in order to obtain an AlOOH/HBsAg complex, then—said AlOOH/HBsAg complex is mixed with the Hib antigen in the presence of cationic amino acids at a concentration of at least 100 mg/l, and of phosphate ions at a concentration of 35 to 45 mMol/l.
    Type: Application
    Filed: January 17, 2013
    Publication date: December 18, 2014
    Inventors: Landry Bertaux, Isabelle Chacornac, Alain Françon, Jean-François Hau, Sandrine Lentsch Graf
  • Publication number: 20140348871
    Abstract: The present invention relates to compositions comprising a construct comprising the A?1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.
    Type: Application
    Filed: August 11, 2014
    Publication date: November 27, 2014
    Applicant: Novartis AG
    Inventors: Peter Ulrich, Katja Baer, Georges Imbert, Marie-Jose Hoellinger, Marie-Emmanuelle Riviere, Ana Graf
  • Patent number: 8895023
    Abstract: Nanoparticles for providing immune responses for the treatment or prophylaxis of infection by infectious agents such as viruses, parasites, bacteria, prions and fungi are described which comprises a core including metal and/or semiconductor atoms, wherein the core is covalently linked to a plurality of ligands, the ligands including a carbohydrate residue capable of stimulating an innate immune response, a T cell helper peptide and a danger signal. This platform may then be adapted by including one or more further ligands capable of producing a specific response to a target infectious agent.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: November 25, 2014
    Assignee: Midatech Limited
    Inventors: Thomas William Rademacher, Phillip Williams
  • Publication number: 20140335158
    Abstract: Complex viruses are assembled from simple protein subunits by sequential and irreversible assembly. During genome packaging in bacteriophages, a powerful molecular motor assembles at the special portal vertex of an empty prohead to initiate packaging. An aspect of the invention relates to the phage T4 packaging machine being highly promiscuous, translocating DNA into finished phage heads as well as into proheads. Single motors can force exogenous DNA into phage heads at the same rate as into proheads and phage heads undergo repeated initiations, packaging multiple DNA molecules into the same head. This shows that the phage DNA packaging machine has unusual conformational plasticity, powering DNA into an apparently passive capsid receptacle, including the highly stable virus shell, until it is full. These features allow for the design of a novel class of nanocapsid delivery vehicles.
    Type: Application
    Filed: July 2, 2014
    Publication date: November 13, 2014
    Inventor: Venigalla B. Rao
  • Patent number: 8883166
    Abstract: Vaccines have been studied that comprise (a) D-T-Pw-HepB-Hib antigens and (b) one or more meningococcal conjugate antigens. A number of improvements and variations of these vaccines have been discovered. The vaccines can be prepared extemporaneously at the time of use by mixing together two components: (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a Hib conjugate and one or more meningococcal conjugates.
    Type: Grant
    Filed: March 16, 2006
    Date of Patent: November 11, 2014
    Assignee: Novartis AG
    Inventors: Mario Contorni, Donatella Mannucci
  • Patent number: 8877204
    Abstract: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: November 4, 2014
    Assignee: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Robert J. Binder
  • Patent number: 8877206
    Abstract: The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: November 4, 2014
    Assignee: PDS Biotechnology Corporation
    Inventors: Weihsu Chen, Weili Yan, Kenya Toney, Gregory Conn, Frank Bedu-Addo, Leaf Huang
  • Publication number: 20140322344
    Abstract: A vaccine preparation for treating cancer includes a complex of a hydrophobized polysaccharide and at least one synthetic long peptide derived from a tumor-specific antigenic protein and/or a pathogen-derived antigenic protein. The at least one synthetic long peptide contains at least one CD8+ cytotoxic T-cell recognition epitope and at least one CD4+ helper T-cell recognition epitope. The complex is simultaneously administered to the patient with at least one immunopotentiating agent.
    Type: Application
    Filed: August 30, 2012
    Publication date: October 30, 2014
    Applicants: National University Corporation Tokyo Medical and Dental University, MIE University
    Inventors: Hiroshi Shiku, Naozumi Harada, Daisuke Muraoka, Kazunari Akiyoshi
  • Publication number: 20140322262
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.
    Type: Application
    Filed: April 9, 2012
    Publication date: October 30, 2014
    Inventors: Leonard D. Spicer, Patrick N. Reardon, Barton F. Haynes, S. Munir Alam
  • Patent number: 8815249
    Abstract: Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope, or said encoded protein or peptide. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide, or said encoded protein or peptide.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: August 26, 2014
    Assignee: Antigen Express, Inc.
    Inventors: Robert Humphreys, Minzhen Xu
  • Publication number: 20140234360
    Abstract: Disclosed are immunogenic conjugates having the general formula: HA2-XXX-Pr, where HA2 is the influenza HA2 fusion peptide or a portion thereof, XXX is a linker and Pr is the carrier. Methods of producing an immune response in a subject using the disclosed immunogenic conjugates, as well as methods of treating, ameliorating or preventing influenza infection, are also disclosed.
    Type: Application
    Filed: September 28, 2012
    Publication date: August 21, 2014
    Applicant: The United States of America, as represented by the Secretary, Dept.of Health and Human Services
    Inventors: Joanna Kubler-Kielb, Jerry Keith, Rachel Schneerson, Zuzana Biesova
  • Publication number: 20140234353
    Abstract: The invention provides a method of obtaining a population of antigen-specific T cells from peripheral blood of a host. An embodiment of the method of the invention comprises (i) dividing PBMCs from peripheral blood of a host into more than one sub-population; (ii) contacting the PBMCs with an antigen and IL-2; (iii) obtaining a sample of PBMCs from each sub-population; (iv) identifying an antigen-reactive sub-population by determining by high throughput quantitative PCR the expression of a factor produced by the PBMCs of each sample; (v) dividing the antigen-reactive sub-population into microcultures; (vi) identifying the antigen-reactive microculture; and (vii) expanding the microculture, thereby obtaining a population of T cells specific for the antigen. The invention also provides a population of T cells obtained by the inventive method, a pharmaceutical composition comprising the same, and a method of treating a disease in a host using the pharmaceutical composition.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 21, 2014
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventor: Udai S. Kammula
  • Publication number: 20140220083
    Abstract: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.
    Type: Application
    Filed: July 6, 2012
    Publication date: August 7, 2014
    Inventors: Luis Brito, Michelle Chan, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Publication number: 20140205628
    Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.
    Type: Application
    Filed: December 16, 2013
    Publication date: July 24, 2014
    Applicant: WORLD FORCE TECHNOLOGIES, LLC
    Inventors: Thomas W. Konowalchuk, Jack Konowalchuk
  • Publication number: 20140205629
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 24, 2014
    Applicant: AlphaVax, Inc.
    Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
  • Patent number: 8784825
    Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: July 22, 2014
    Assignee: Taiga Biotechnologies, Inc.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Patent number: 8765666
    Abstract: The embodiment of the invention is a virus-like particle vector, a process for the manufacture thereof, use of the virus-like particle vector and a pharmaceutical composition, which contains the virus-like particle vector. The vector is intended for the delivery of therapeutic agents into specific mammalian tissues, especially low molecular weight agents, in particular low molecular weight anti-cancer drugs into cancer tissues. More specifically, the invention relates to the virus-like particle vector, which constitutes an adenoviral dodecahedron with the therapeutic substance encapsulated or covalently linked.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: July 1, 2014
    Assignee: Instytut Bio chemii i Biofizki PAN
    Inventors: Ewa Szolajska, Jadwiga Chroboczek, Monika Zochowska
  • Publication number: 20140170172
    Abstract: A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: PIN Pharma, Inc.
    Inventor: David I. Cohen